{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:27:40Z","timestamp":1793273260276,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.cellimm.2018.02.011","type":"journal-article","created":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T12:10:43Z","timestamp":1519042243000},"page":"77-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"special_numbering":"C","title":["Interleukin-1\u03b2, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-\u03b1 levels in CSF and serum in relation to the clinical diversity of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"327","author":[{"given":"M.N.","family":"Karpenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Vasilishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Gromova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.M.","family":"Muruzheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bernadotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cellimm.2018.02.011_b0005","doi-asserted-by":"crossref","first-page":"a009381","DOI":"10.1101\/cshperspect.a009381","article-title":"Inflammation and adaptive immunity in Parkinson\u2019s disease","volume":"2","author":"Mosley","year":"2012","journal-title":"Cold Spring Harb Perspect. Med."},{"issue":"9","key":"10.1016\/j.cellimm.2018.02.011_b0010","doi-asserted-by":"crossref","first-page":"a009373","DOI":"10.1101\/cshperspect.a009373","article-title":"Innate inflammation in Parkinson\u2019s disease","volume":"2","author":"Perry","year":"2012","journal-title":"Cold Spring Harb Perspect. Med."},{"issue":"1","key":"10.1016\/j.cellimm.2018.02.011_b0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neulet.2009.10.062","article-title":"Serum levels of interleukin-6 are elevated in patients with Parkinson\u2019s disease and correlate with physical performance","volume":"486","author":"Scalzo","year":"2010","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.cellimm.2018.02.011_b0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neulet.2008.06.040","article-title":"Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. 2008","volume":"441","author":"Brodacki","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.cellimm.2018.02.011_b0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuroscience.2012.02.001","article-title":"Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity","volume":"208","author":"Gillardon","year":"2012","journal-title":"Neuroscience"},{"issue":"23","key":"10.1016\/j.cellimm.2018.02.011_b0030","doi-asserted-by":"crossref","first-page":"9592","DOI":"10.1523\/JNEUROSCI.5610-12.2013","article-title":"MHCII is required for \u03b1-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration","volume":"33","author":"Harms","year":"2013","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.cellimm.2018.02.011_b0035","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1523\/JNEUROSCI.5601-11.2012","article-title":"LRRK2 inhibition attenuates microglial inflammatory responses","volume":"32","author":"Moehle","year":"2012","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.cellimm.2018.02.011_b0040","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/glia.20947","article-title":"Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson\u2019s disease","volume":"58","author":"Rojo","year":"2010","journal-title":"Glia."},{"key":"10.1016\/j.cellimm.2018.02.011_b0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.nbd.2014.08.011","article-title":"Dynamic changes in pro-and anti-inflammatory cytokines in microglia after PPAR-\u03b3 agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson\u2019s disease","volume":"71","author":"Pisanu","year":"2014","journal-title":"Neurobiol Dis."},{"issue":"1","key":"10.1016\/j.cellimm.2018.02.011_b0050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/aje\/kwm260","article-title":"Peripheral inflammatory biomarkers and risk of Parkinson\u2019s disease","volume":"167","author":"Chen","year":"2008","journal-title":"Am J Epidemiol."},{"issue":"5","key":"10.1016\/j.cellimm.2018.02.011_b0055","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000292020","article-title":"Molecular inflammatory mediators in peripheral nerve degeneration and regeneration","volume":"17","author":"C\u00e1mara-Lemarroy","year":"2010","journal-title":"Neuroimmunomodulation"},{"issue":"2","key":"10.1016\/j.cellimm.2018.02.011_b0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-5728(94)90005-1","article-title":"Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier","volume":"55","author":"Gutierrez","year":"1994","journal-title":"J. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.cellimm.2018.02.011_b0065","doi-asserted-by":"crossref","first-page":"e28032","DOI":"10.1371\/journal.pone.0028032","article-title":"Increased Intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson\u2019s disease","volume":"6","author":"Forsyth","year":"2011","journal-title":"PLoS One."},{"issue":"11","key":"10.1016\/j.cellimm.2018.02.011_b0070","first-page":"CD008454","article-title":"Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies","volume":"9","author":"Rees","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cellimm.2018.02.011_b0075","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.brainres.2014.04.014","article-title":"PAR2-mediated epigenetic upregulation of \u03b1 -synuclein contributes to the pathogenesis of Parkinson \u2019 s disease","volume":"1565","author":"Liu","year":"2014","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.cellimm.2018.02.011_b0080","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/01616412.2015.1133026","article-title":"Levels of IL-8 and TNF-\u03b1 decrease in Parkinson\u2019s disease","volume":"38","author":"Gupta","year":"2016","journal-title":"Neurol Res."},{"issue":"4","key":"10.1016\/j.cellimm.2018.02.011_b0085","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bbi.2007.10.001","article-title":"Interleukin-18 produced by peripheral blood cells is increased in Alzheimer\u2019s disease and correlates with cognitive impairment","volume":"22","author":"Boss\u00f9","year":"2008","journal-title":"Brain Behav. Immun."},{"issue":"6","key":"10.1016\/j.cellimm.2018.02.011_b0090","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jnc.12263","article-title":"IL-1\u03b2 and TNF-\u03b1 induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase","volume":"125","author":"Ye","year":"2013","journal-title":"J. Neurochem."},{"issue":"9","key":"10.1016\/j.cellimm.2018.02.011_b0095","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.7150\/ijbs.4679","article-title":"Interleukin-6, a major cytokine in the central nervous system","volume":"8","author":"Erta","year":"2012","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.cellimm.2018.02.011_b0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0014-5793(91)80737-N","article-title":". Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer\u2019s disease cortices","volume":"285","author":"Bauer","year":"1991","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.cellimm.2018.02.011_b0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00406-003-0405-x","article-title":"Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer\u2019s disease. Results of a pilot study","volume":"253","author":"Bagli","year":"2003","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.cellimm.2018.02.011_b0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0304-3940(94)90508-8","article-title":"Interleukin-1, interleukin-6, epidermal growth factor and transforming growth factor are elevated in the brain from parkinsonian patients","volume":"180","author":"Mogi","year":"1994","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.cellimm.2018.02.011_b0115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1600-0404.1999.tb00721.x","article-title":"Association of circulating TNF-a and IL-6 with ageing and parkinsonism","volume":"100","author":"Dobbs","year":"1999","journal-title":"Acta Neurol Scand."},{"issue":"10","key":"10.1016\/j.cellimm.2018.02.011_b0120","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2174\/138955709789055199","article-title":"Peripheral chemo-cytokine profiles in Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"9","author":"Reale","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.cellimm.2018.02.011_b0125","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.expneurol.2014.08.019","article-title":"Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1\u03b2","volume":"261","author":"Mu\u00f1oz","year":"2014","journal-title":"Exp Neurol."},{"issue":"6","key":"10.1016\/j.cellimm.2018.02.011_b0130","first-page":"474","article-title":"The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson\u2019s disease","volume":"51","author":"Menza","year":"2010","journal-title":"Psychosomatics."},{"issue":"5","key":"10.1016\/j.cellimm.2018.02.011_b0135","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A meta-analysis of cytokines in major depression","volume":"67","author":"Dowlati","year":"2010","journal-title":"Biol Psychiatry."},{"issue":"2","key":"10.1016\/j.cellimm.2018.02.011_b0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","article-title":"Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis","volume":"71","author":"Howren","year":"2009","journal-title":"Psychosom Med."},{"key":"10.1016\/j.cellimm.2018.02.011_b0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuroscience.2013.04.060","article-title":"Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications","volume":"246","author":"Felger","year":"2013","journal-title":"Neuroscience."},{"issue":"12","key":"10.1016\/j.cellimm.2018.02.011_b0150","doi-asserted-by":"crossref","first-page":"e29142","DOI":"10.1371\/journal.pone.0029142","article-title":"Cytokine production by leukocytes of military personnel with depressive symptoms after deployment to a combat-zone: a prospective, longitudinal study","volume":"6","author":"van Zuiden","year":"2011","journal-title":"PLoS ONE."},{"issue":"3","key":"10.1016\/j.cellimm.2018.02.011_b0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"5","key":"10.1016\/j.cellimm.2018.02.011_b0160","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.cellimm.2018.02.011_b0165","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/mds.22875","article-title":"Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times","volume":"25","author":"Zhao","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.cellimm.2018.02.011_b0170","series-title":"Third Symposium on Parkinson\u2019s Disease, Royal College of Surgeons in Edinburgh., Grillingham, I.M.L. Donaldson","first-page":"152","article-title":"Projection Techniques for Evaluating Surgery in Parkinson\u2019s Disease. A.C. Jr. England","author":"Schwab","year":"1968"},{"key":"10.1016\/j.cellimm.2018.02.011_b0175","series-title":"Unified rating scale for parkinson\u2019s disease. in: recent developments in Parkinson\u2019s disease","first-page":"153","author":"Fahn","year":"1987"},{"issue":"5","key":"10.1016\/j.cellimm.2018.02.011_b0180","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet. Neurol."},{"issue":"3","key":"10.1016\/j.cellimm.2018.02.011_b0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.cellimm.2018.02.011_b0190","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2190\/5A0F-936P-VG8N-0F5R","article-title":"The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients","volume":"24","author":"Manos","year":"1994","journal-title":"Int. J. Psychiatry Med."},{"issue":"11","key":"10.1016\/j.cellimm.2018.02.011_b0195","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","article-title":"The FAB: a frontal assessment battery at bedside","volume":"55","author":"Dubois","year":"2000","journal-title":"Neurology."},{"key":"10.1016\/j.cellimm.2018.02.011_b0200","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch. Gen. Psychiatry."},{"issue":"6","key":"10.1016\/j.cellimm.2018.02.011_b0205","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.cellimm.2018.02.011_b0210","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11481-012-9401-0","article-title":"Microglial activation and antioxidant responses induced by the Parkinson's disease protein \u03b1-synuclein","volume":"8","author":"B\u00e9raud","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"5","key":"10.1016\/j.cellimm.2018.02.011_b0215","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3892\/br.2014.296","article-title":"Association of NQO1 and TNF polymorphisms with Parkinson's disease: a meta-analysis of 15 genetic association studies","volume":"2","author":"Dai","year":"2014","journal-title":"Biomed Rep."},{"key":"10.1016\/j.cellimm.2018.02.011_b0220","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13024-017-0158-z","article-title":"Defining the contribution of neuroinflammation to Parkinson\u2019s disease in humanized immune system mice","volume":"12","author":"Manocha","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.cellimm.2018.02.011_b0225","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1749-6632.2000.tb05373.x","article-title":"The role of pro- and antiinflammatory cytokines in neurodegeneration","volume":"917","author":"Allan","year":"2000","journal-title":"Ann. NY Acad. Sci."},{"issue":"4","key":"10.1016\/j.cellimm.2018.02.011_b0230","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00415-009-5353-6","article-title":"Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression","volume":"257","author":"P\u00e5lhagen","year":"2010","journal-title":"J. Neurol."},{"key":"10.1016\/j.cellimm.2018.02.011_b0235","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bbi.2014.06.003","article-title":"Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress","volume":"42","author":"Lindqvist","year":"2014","journal-title":"Brain Behav. Immun."},{"issue":"2","key":"10.1016\/j.cellimm.2018.02.011_b0240","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12325-016-0474-7","article-title":"Modulation of neuroinflammation in the central nervous system: role of chemokines and sphingolipids","volume":"34","author":"Gualtierotti","year":"2017","journal-title":"Adv. Ther."}],"updated-by":[{"DOI":"10.1016\/j.cellimm.2018.08.007","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000}}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874918300716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874918300716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:56:43Z","timestamp":1757804203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874918300716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":48,"alternative-id":["S0008874918300716"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2018.02.011","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-1\u03b2, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-\u03b1 levels in CSF and serum in relation to the clinical diversity of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2018.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}